Aim and Objective: MAO inhibitors have a significant effect on the nervous system since
they act in regulation of neurotransmitter concentrations. Neurotransmitter levels are critical for a
healthy nervous system. MAO inhibitors can be used in the treatment of neurological disorders such
as depression, Parkinson's disease and Alzheimer's disease, as the increase or decrease of some
neurotransmitter concentrations is associated with these neurological disorders. This study was
conducted to discover new and active MAO inhibitor drug candidates.
Materials and Methods: New pyrazoline derivatives have been designed with the molecular docking
approach and interactions of our compounds with the MAO enzyme have been investigated using the
Autodock 4.2 program. The designed pyrazoline derivative compounds were synthesized by the
reaction of the chalcones and hydrazides in ethanol. hMAO inhibitory activities of the newly
synthesized compounds were investigated by fluorimetric method. In vitro cytotoxicity of five most
potent inhibitors were tested in HepG2 cells.
Results: (3-(5-bromo-2-hydroxyphenyl)-5-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl) methanone
(5i) and (3-(2-hydroxy-4-methoxy phenyl)-5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl)
methanone (5l) inhibited hMAO-A more potently than moclobemide (Ki values are 0.004±0.001 and
0.005±0.001, respectively). The same two compounds, 5i and 5l, inhibited hMAO-A more
selectively than moclobemide (SI values are 5.55x10-5 and 0.003, respectively). Both of these
compounds were found non toxic at 1 µM, 5 µM and 25µM concentrations.
Conclusion: Two of the newly synthesized compounds, (3-(5-bromo-2-hydroxyphenyl)-5-(4-
methoxyphenyl)-4,5-dihydropyrazol-1-yl)(phenyl)methanone and (3-(2-hydroxy-4-methoxy phenyl)-
5-p-tolyl-4,5-dihydropyrazol-1-yl)(phenyl) methanone were found to be promising MAO-A
inhibitors due to their high inhibitory potency, high selectivity and low toxicity.